Konstantinos Drosatos received his undergraduate degree in Biology from the Aristotle University of Thessaloniki in 2000. He continued with graduate studies in Molecular Biology & Biomedicine at the University of Crete, Greece and Boston University, USA. From 2007 to 2012, he worked as a Post-doctoral Research Scientist at Columbia University and was then promoted to Associate Research Scientist. In 2014, he joined Temple University School of Medicine as a tenure-track Assistant Professor and was promoted to Associate Professor with tenure in 2020. In 2021, he accepted the offer for the Ohio Eminent Scholar position of Professor in Pharmacology & Systems Physiology at the University of Cincinnati, College of Medicine. His graduate training focused on the transcriptional regulation mechanisms of ApoE and the role of ApoE in lipoprotein clearance. In these studies, he demonstrated the importance of the stress activated JNK signaling pathway in the regulation of apoE transcription and created a modified ApoE protein molecule that treats hyperlipidemia. In addition, he discovered that miR370 targets directly hepatic carnitine palmitoyl transferase, an enzyme that regulates fatty acid import in mitochondria. Up to date, he has more than 50 peer-reviewed publications in excellent medical and biosciences journals. His research has been funded by the National Institutes of Health, the American Heart Association, and private foundations. In his postdoctoral training at Columbia University, he studied the effects of aberrant lipid metabolism in cardiac function. He discovered β-adrenergic receptor desensitization as an additional dimension of cardiac lipotoxicity that is controlled by a PKC-dependent mechanism. Driven by his interest in cardiac stress signaling, he initiated a project that demonstrated the importance of cardiac fatty acid oxidation for the treatment of cardiac dysfunction in sepsis. Capitalizing on his training in hepatic and cardiac lipid metabolism, the research of his own lab research focuses on signaling mechanisms that link cardiac stress in diabetes, sepsis and ischemia with altered myocardial and systemic fatty acid metabolism. Their 2016 paper in Circulation Research identified for the first time that KLF5 is a regulator of cardiac fatty acid metabolism in diabetes and was selected for the journal’s editorial. His group then showed that KLF5 is a major driver of diabetic cardiomyopathy and ischemic heart failure. Accordingly, two of their most recent studies about KLF5 in Circulation and Circulation Research have been highlighted in public media, as well as with an editorial in Circulation Research. Another study that delineated how a drug for diabetic patients (tesaglitazar) (JCI Insight, 2019) caused cardiac dysfunction, has drawn attention of public media. Their studies on sepsis have signified the role of cardiac metabolism impairment in the pathophysiology of septic cardiomyopathy. Their 2017 paper in JCI Insight and the 2019 paper in the Journal of Molecular & Cellular Cardiology about the importance of cardiac fatty acid oxidation and mitochondrial function in treating septic cardiac dysfunction has been based on their early findings about the importance of the energetic machinery for the prevention of heart failure in sepsis. In 2019, they published a technical paper in the Journal of the AHA that characterized the cardiovascular complications in preclinical mouse models of sepsis, which, following the redefinition of the disease in 2016, has been of significant importance for the sepsis field. Their 2020 JCI Insight paper that identified cardiomyocyte-derived BNP as a driver of septic hypotension and delineated the underlying signaling mechanism was highlighted in the “JCI-This month” section. He is an elected Fellow of the Basic Cardiovascular Sciences Council of the American Heart Association, the recipient of the 2014 Outstanding Early Career Investigator Award of the American Heart Association-Basic Cardiovascular Sciences Council, the recipient of the 2017 Early Research Investigator Award of the Medical School at Temple University, a Visiting Professor of the Center for Systems Biomedicine at the UCLA, and external faculty of the University of Crete Medical School (Greece). He has founded and served as the president of two scientific networks of Greek biomedical scientists and physicians that live abroad: The Hellenic Bioscientific Association of the USA and the World Hellenic Biomedical Association. During his tenure as the president of these societies he organized national meetings and an annual international summer school for medical and biosciences students. Currently, he is the Vice-President of the ARISTEiA-Institute for the Advancement of Research & Education in Arts, Sciences and Technology, chair-elect of the Mid-Career Committee of the International Society for Heart Research, and member of the Membership and Communications Committee of Basic Cardiovascular Sciences Council of the American Heart Association. He has been serving as the co-chair of the organizing committee of international conferences that were held in the USA, Japan and Europe. He is the co-founder of the top-level Olympiad in Cardiovascular Medicine that takes place every 4 years in Greece.